- Home
- BLIN vs CMMB Comparison
BLIN vs CMMB Comparison
Compare BLIN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- CMMB
- Stock Information
- Founded
- BLIN 2000
- CMMB 2004
- Country
- BLIN United States
- CMMB Israel
- Employees
- BLIN N/A
- CMMB N/A
- Industry
- BLIN EDP Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- BLIN Technology
- CMMB Health Care
- Exchange
- BLIN Nasdaq
- CMMB Nasdaq
- Market Cap
- BLIN 16.5M
- CMMB 13.7M
- IPO Year
- BLIN 2007
- CMMB N/A
- Fundamental
- Price
- BLIN N/A
- CMMB $3.45
- Analyst Decision
- BLIN Strong Buy
- CMMB Strong Buy
- Analyst Count
- BLIN 1
- CMMB 2
- Target Price
- BLIN $4.62
- CMMB $26.50
- AVG Volume (30 Days)
- BLIN 209.5K
- CMMB 260.6K
- Earning Date
- BLIN 08-14-2025
- CMMB 11-13-2025
- Dividend Yield
- BLIN N/A
- CMMB N/A
- EPS Growth
- BLIN N/A
- CMMB N/A
- EPS
- BLIN N/A
- CMMB N/A
- Revenue
- BLIN $15,375,000.00
- CMMB N/A
- Revenue This Year
- BLIN $2.45
- CMMB N/A
- Revenue Next Year
- BLIN $16.36
- CMMB N/A
- P/E Ratio
- BLIN N/A
- CMMB N/A
- Revenue Growth
- BLIN 0.54
- CMMB N/A
- 52 Week Low
- BLIN $1.05
- CMMB $2.39
- 52 Week High
- BLIN $2.80
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- BLIN 54.45
- CMMB 69.78
- Support Level
- BLIN $1.35
- CMMB $3.03
- Resistance Level
- BLIN $1.59
- CMMB $3.55
- Average True Range (ATR)
- BLIN 0.08
- CMMB 0.21
- MACD
- BLIN 0.01
- CMMB 0.05
- Stochastic Oscillator
- BLIN 49.19
- CMMB 91.23
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.